Pages that link to "Q49553520"
Jump to navigation
Jump to search
The following pages link to Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia (Q49553520):
Displaying 50 items.
- Posttransplant chimeric antigen receptor therapy (Q47550219) (← links)
- Immunotherapy: CAR T cell therapy efficacious against B-ALL across age groups (Q49831065) (← links)
- Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. (Q52369234) (← links)
- Cellular therapies: Day by day, all the way. (Q52569021) (← links)
- CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing? (Q52658445) (← links)
- Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. (Q52721068) (← links)
- Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives. (Q54213151) (← links)
- Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry? (Q55043332) (← links)
- CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. (Q55193924) (← links)
- Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? (Q55292778) (← links)
- Cytokine release syndrome. (Q55438228) (← links)
- Chimeric antigen receptor T‑cell therapy—a hematological success story. (Q55443158) (← links)
- CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease (Q56334080) (← links)
- Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children (Q56379419) (← links)
- Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector (Q56889227) (← links)
- Toward the potential cure of leukemias in the next decade (Q57020375) (← links)
- A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML (Q57039806) (← links)
- Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy (Q57045402) (← links)
- Allogeneic CAR-T Cells: More than Ease of Access? (Q57053387) (← links)
- Cancer immunotherapy with CAR-T cells - behold the future (Q57171765) (← links)
- Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage (Q57279955) (← links)
- Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting (Q57293724) (← links)
- Management of older adults with acute lymphoblastic leukemia: challenges & current approaches (Q57301411) (← links)
- CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells (Q57471771) (← links)
- Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report (Q57490418) (← links)
- In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas (Q57493527) (← links)
- Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again (Q58087985) (← links)
- Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies (Q58088141) (← links)
- Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma (Q58109286) (← links)
- Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies (Q58548495) (← links)
- CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge (Q58572502) (← links)
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study (Q58577391) (← links)
- Recommendations for the Assessment and Management of Measurable Residual Disease in Adults With Acute Lymphoblastic Leukemia: A Consensus of North American Experts (Q58609171) (← links)
- Phase 1 Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma (Q58609590) (← links)
- Engineering CAR-T Cells for Improved Function Against Solid Tumors (Q58694793) (← links)
- Cytokine release syndrome: grading, modeling, and new therapy (Q58700983) (← links)
- Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL (Q58724470) (← links)
- The biological basis and clinical symptoms of CAR-T therapy-associated toxicites (Q58765358) (← links)
- The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma (Q58788254) (← links)
- Tumour tamed by transfer of one T cell (Q59068304) (← links)
- Molecular landscape and targeted therapy of acute myeloid leukemia (Q59130314) (← links)
- 4-1BB enhancement of CAR T function requires NF-κB and TRAFs (Q59134955) (← links)
- Universal CARs, universal T cells, and universal CAR T cells (Q59326961) (← links)
- No free rides: management of toxicities of novel immunotherapies in ALL, including financial (Q59333343) (← links)
- CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report (Q59336601) (← links)
- Making CAR T Cells a Solid Option for Solid Tumors (Q59341206) (← links)
- Prevention of allergy by virus-like nanoparticles (VNP) delivering shielded versions of major allergens in a humanized murine allergy model (Q59356207) (← links)
- CAR-T Cell Therapy: A Door Is Open to Find Innumerable Possibilities of Treatments for Cancer Patients (Q59809431) (← links)
- CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia (Q59809962) (← links)
- A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia (Q59813037) (← links)